Standardizing Extended Endocrine Therapy Recommendations

JADPRO Live 2023 - Standardizing Extended Endocrine Therapy Decision-MakingПодробнее

The Predictive Power of the Breast Cancer Index (H/I) Biomarker-SABCS 2022Подробнее

Extended Endocrine Therapy: Who Will Benefit?Подробнее

Guideline Updates for Extended Endocrine Therapy Decision-Making in HR+, Early-Stage Breast CancerПодробнее

Exploring Extended Adjuvant Endocrine Therapy for HR+ Breast CancerПодробнее

Education Session: Trends in Adjuvant Endocrine TherapyПодробнее

Strategies to Standardize use of Breast Cancer Index TestПодробнее

Guideline Updates for Extended Endocrine Therapy Decision-Making in HR+, Early-Stage Breast CancerПодробнее

BCI: A Unique, Guideline-Recognized Test to Predict Benefit of Extended Endocrine TherapyПодробнее

Updates in Extended Endocrine Therapy for HR+ Breast Cancer | ASCO21 & National Practice GuidelinesПодробнее

The Role of BCI in Extended Endocrine Therapy Decision MakingПодробнее

Challenges With Patient Selection for Extended Adjuvant Endocrine Therapy in Breast CancerПодробнее

Adjuvant endocrine therapy for breast cancer: optimal durations and regimensПодробнее

Breast Cancer Index, Extended Endocrine Therapy | Elizabeth Ott, PA | 2022 West Oncology APP UpdatesПодробнее

Consideration of Side Effects in Extended Endocrine Therapy Decision MakingПодробнее

Endocrine Treatment in Breast CancerПодробнее

Understanding the ABCSG Trial and Patient Selection for Extended Endocrine TherapyПодробнее

Breast Cancer: Extended Adjuvant Endocrine TherapyПодробнее

BCI as a Predictive Biomarker for Extended Endocrine Therapy BenefitПодробнее